Endocrine experts at Crinetics bag $63.5M to push R&D on an experimental pill for acromegaly
It’s been more than two years since Crinetics bagged its $40 million launch round to get started on pipeline building. And now that they’re into the clinic with their first drug, they just scored an extra $63.5 million to pursue some clinical proof-of-concept data to show the world if they’re on the right track.
San Diego-based Crinetics was founded by three key players out of Neurocrine Biosciences: CEO R. Scott Struthers, VP of chemistry Frank Zhu and Stephen Betz, the VP of biology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
